Arca
Skip to content
Tools
Tools

GSC1: 1,3-beta-glucan synthase

Protein in Candida that 4 drugs act on.

  • Drugs that act on it: 4
  • Approved: 4
  • In phases 1 to 3: 0
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on GSC1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4

Approved4

  • Caspofungin
  • Micafungin
  • Anidulafungin
  • Ibrexafungerp

Phase 30

    Phase 20

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: 1,3-beta-glucan synthase inhibitor.
        CaspofunginApprovedMerck & Co. (MSD)Small moleculeInhibitor7
        MicafunginApprovedAstellas PharmaSmall moleculeInhibitor3
        AnidulafunginApprovedPfizerSmall moleculeInhibitor2
        IbrexafungerpBoxed warningApprovedGSKSmall moleculeInhibitor1

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 9 in all, from ClinicalTrials.gov.
        Echinocandin Added to Standard Treatment for Severe Pneumocystis PneumoniaAnidulafungin, Caspofungin, MicafunginPhase 3Not yet recruitingMcGill University Health Centre/Research Institute of the McGill University Health CentreOct 28, 2026
        Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN TrialCaspofunginPhase 4Not yet recruitingOliver Cornely, MDAug 26, 2026
        Antibiotic Impregnated Beads in OsteomyelitisMicafunginPhase 4Not yet recruitingUniversity of ArizonaJul 18, 2025
        A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated CandidemiaAnidulafungin, Caspofungin, Micafungin—Not yet recruitingAugusta UniversityApr 3, 2025
        CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis PneumoniaCaspofunginPhase 1 / Phase 2RecruitingUniversity Hospital, ToursMar 25, 2025
        Caspofungin for Pneumocystis Pneumonia in PLWHIV.Caspofungin—RecruitingInstituto Nacional de Enfermedades RespiratoriasNov 15, 2024
        Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant OutcomesIbrexafungerp—RecruitingGlaxoSmithKlineJun 18, 2023
        A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.CaspofunginPhase 3RecruitingBasilea PharmaceuticaJun 16, 2022
        PK/PD of Caspofungin in Children Severe InfectionCaspofungin—RecruitingChildren's Hospital of Fudan UniversityJul 14, 2021

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364673, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.